Abivax shares are trading lower. The company announced topline results from the Phase 3 ABTECT maintenance trial evaluating obefazimod in adults with moderately to severely active ulcerative colitis.

Benzinga Newsdesk www.benzinga.com Negative 48.6%

Neg 48.6% Neu 0% Pos 0%

Comments

No comments yet. Be the first!